Literature DB >> 8642048

Circulating intercellular adhesion molecule 1 predicts non-specific elevation of alpha 1-fetoprotein.

E Falleti1, C Fabris, M Pirisi, G Soardo, D Vitulli, P Toniutto, E Bartoli, N Bortolotti, F Gonano.   

Abstract

Molecules governing cellular interactions have been suggested to be involved in the spurious elevation of alpha 1-fetoprotein (AFP) in non-neoplastic liver disease. To explore this controversial issue, we measured AFP, circulating intercellular adhesion molecule 1 (cICAM-1), and common liver function tests in 111 patients (71 male, 40 female). Eighty-four patients had non-neoplastic chronic liver disease and 27 had hepatocellular carcinoma. The concentration of cICAM-1 was determined immunoenzymatically. In patients with non-neoplastic chronic liver disease, univariate analysis demonstrated a significant correlation between AFP and cholinesterase (R = -0.397, P < 0.001), aspartate aminotransferase (R = 0.421, P < 0.001), bilirubin (R = 0.231, P < 0.05) and cICAM-1 (R = 0.430, P < 0.001). Multivariate analysis among these variables and AFP indicated cICAM-1 to be the strongest independent predictor of AFP. We conclude that cICAM-1 compares favourably with liver function tests in predicting non-specific AFP variations in non-neoplastic chronic liver disease, suggesting a link between targeting of the inflammatory damage to the hepatocyte and development of neoplasia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8642048     DOI: 10.1007/bf01220805

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  26 in total

1.  Markedly increased alpha-fetoprotein concentration in serum in alcoholic liver disease: malignant tumor or nonneoplastic changes?

Authors:  J Kaczynski; R Jagenburg; G Lindstedt; S Wallerstedt
Journal:  Clin Chem       Date:  1992-05       Impact factor: 8.327

2.  [A kinetic method for determination of the activity of pseudocholinesterase (acylcholine acyl-hydrolase 3.1.1.8.)].

Authors:  M Knedel; R Böttger
Journal:  Klin Wochenschr       Date:  1967-03-15

3.  A form of circulating ICAM-1 in human serum.

Authors:  R Rothlein; E A Mainolfi; M Czajkowski; S D Marlin
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

4.  Circulating intercellular adhesion molecule-1 (cICAM-1) concentration in liver disease. Relationship with cholestasis and functioning hepatic mass.

Authors:  M Pirisi; E Falleti; C Fabris; G Soardo; P Toniutto; D Vitulli; F Pezzetta; N Bortolotti; F Gonano; E Bartoli
Journal:  Am J Clin Pathol       Date:  1994-11       Impact factor: 2.493

5.  AFP-producing cells in hepatitis and in liver cirrhosis.

Authors:  S Sakamoto; A Yachi; T Anzai; T Wada
Journal:  Ann N Y Acad Sci       Date:  1975-08-22       Impact factor: 5.691

6.  Transforming growth factor beta 1 differentially regulates alpha-fetoprotein and albumin in HuH-7 human hepatoma cells.

Authors:  K Nakao; K Nakata; S Mitsuoka; A Ohtsuru; A Ido; M Hatano; Y Sato; T Nakayama; M Shima; Y Kusumoto
Journal:  Biochem Biophys Res Commun       Date:  1991-02-14       Impact factor: 3.575

7.  Activation of nuclear protooncogenes and alpha-fetoprotein gene in rat liver during the acute inflammatory reaction.

Authors:  D Bernuau; A Moreau; I Tournier; L Legres; G Feldmann
Journal:  Liver       Date:  1993-04

8.  Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: relationship to disease activity and cirrhosis.

Authors:  G Zöhrens; T Armbrust; U Pirzer; K H Meyer zum Büschenfelde; G Ramadori
Journal:  Hepatology       Date:  1993-10       Impact factor: 17.425

9.  Serum alpha-fetoprotein in patients following partial hepatectomy.

Authors:  N Nagasue; K Inokuchi; M Kobayashi; R Kanashima
Journal:  Dig Dis Sci       Date:  1980-04       Impact factor: 3.199

10.  Serum alpha-fetoprotein in patients with massive hepatic necrosis.

Authors:  J R Bloomer; T A Waldmann; K R McIntire; G Klatskin
Journal:  Gastroenterology       Date:  1977-03       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.